Viridian Therapeutics
6200 Lookout Road
Suite 100
Boulder
Colorado
80301
United States
Tel: 720-643-5200
Fax: 720-643-5201
203 articles about Viridian Therapeutics
-
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
7/10/2023
Viridian Therapeutics, Inc. announced positive preliminary data from its ongoing Phase 1/2 clinical trial of VRDN-001, an investigational full antagonist antibody to the insulin-like growth factor 1 receptor, in patients with chronic thyroid eye disease.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 06, 2023
7/6/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 101,000 shares of the Company’s common stock to two new employees on July 5, 2023.
-
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
6/13/2023
Viridian Therapeutics, Inc. announced that multiple abstracts featuring data on the Company’s lead investigational therapy for the treatment of thyroid eye disease will be presented at the Annual Meeting of the Endocrine Society to be held June 15-18, 2023, in Chicago, Illinois.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 05, 2023
6/5/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 315,000 shares of the Company’s common stock to three new employees on June 1, 2023.
-
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/9/2023
Viridian Therapeutics, Inc., a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced financial results and provided a corporate update for the first quarter ended March 31, 2023.
-
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
5/8/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023
5/4/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,000 shares of the Company’s common stock to two new employees on May 1, 2023.
-
Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
5/2/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced it will host a webcast and conference call on Tuesday, May 9, 2023 at 4:30 p.m. ET to discuss its first quarter 2023 financial results and provide a corporate update.
-
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
4/20/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced that multiple abstracts featuring updates on the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—including new preclinical research on VRDN-003—will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2023), to be held April 23-27, 2023, in New Orleans, Louisiana.
-
UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
4/20/2023
Viridian Therapeutics, Inc. announced that multiple abstracts featuring updates on the Company’s investigational therapies for the treatment of thyroid eye disease —including new preclinical research on VRDN-003—will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, to be held April 23-27, 2023, in New Orleans, Louisiana.
-
Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
4/12/2023
Viridian Therapeutics, Inc. today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO).
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2023
4/4/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Company’s Board of Directors or the Compensation Committee thereof, as applicable, approved the grant of non-qualified stock options to purchase an aggregate of 350,000 shares of the Company’s common stock to two new employees on March 30 and April 3, 2023, respectively.
-
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
3/8/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022.
-
Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
3/7/2023
Viridian Therapeutics, Inc. today announced that multiple abstracts on VRDN-001 and VRDN-002—the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—will be presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), to be held March 11 to 16, 2023, in Orlando, Florida.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023
3/3/2023
Viridian Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 337,000 shares of the Company’s common stock to three new employees on March 1, 2023.
-
Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
3/1/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, March 8, 2023 at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results.
-
Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference
2/28/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced that senior management will present at Cowen’s 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 1:30 p.m. ET in Boston, MA.
-
Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
2/7/2023
Viridian Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 1:00 p.m. ET.
-
Viridian Appoints Scott Myers as President and Chief Executive OfficerTransition highlights Viridian’s progression towards becoming a fully-integrated biopharmaceutical company
2/6/2023
Viridian Therapeutics, Inc. today announced that the Company has appointed Scott Myers as President and Chief Executive Officer, and a member of the Board of Directors, effective today February 6, 2023.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - February 02, 2023
2/2/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 332,000 shares of the Company’s common stock to four new employees on February 1, 2023.